10-Q: Altimmune Reports Q3 2025 Results, Advances Pemvidutide Trials

Altimmune, a late clinical-stage biopharmaceutical company, reported a reduced net loss in Q3 2025, bolstered its cash position, and announced positive clinical trial updates for its lead drug candidate, pemvidutide, despite facing new legal challenges.

Summary

• Net loss for the three months ended September 30, 2025, improved to $19.0 million, down from $22.8 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, improved to $60.7 million, compared to $71.9 million for the same period in 2024.
• Research and development expenses decreased by 24% to $15.0 million for the three months, and by 23% to $48.0 million for the nine months ended September 30, 2025, primarily due to reduced MASH trial enrollment and manufacturing costs, partially offset by new AUD and ALD trial expenses.
• General and administrative expenses increased by 19% to $5.9 million for the three months, and by 11% to $17.6 million for the nine months ended September 30, 2025, mainly due to higher stock compensation, labor-related expenses, and professional services.
• Cash, cash equivalents, restricted cash, and short-term investments totaled $210.8 million as of September 30, 2025, up from $36.9 million in total cash, cash equivalents and restricted cash at December 31, 2024.
• Topline 24-week efficacy results from the IMPACT Phase 2b trial in MASH showed 58% and 52% of subjects achieved MASH resolution without worsening fibrosis at 1.2 mg and 1.8 mg pemvidutide doses, respectively, compared to 20% for placebo (p<0.0001 for both doses).
• Pemvidutide demonstrated mean weight loss of 4.8% (1.2 mg) and 5.8% (1.8 mg) versus 0.5% for placebo (p<0.001) in the MASH trial.
• The U.S. FDA granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD) on August 19, 2025.
• Enrollment for the RECLAIM Phase 2 trial in AUD was completed ahead of schedule on November 3, 2025, with topline results expected in 2026.
• The RESTORE Phase 2 trial for Alcohol-Associated Liver Disease (ALD) enrolled its first patient on July 9, 2025.
• A $15.0 million first tranche of a $100.0 million term loan facility with Hercules Capital, Inc. was drawn on May 13, 2025, subsequently amended to $125.0 million with a $20.0 million second tranche drawn on November 5, 2025.
• Raised $81.9 million in net proceeds from at-the-market (ATM) offerings during the nine months ended September 30, 2025, with $65.4 million remaining available under the 2025 ATM program.
• Subsequent to quarter-end, an additional $33.8 million in net proceeds was raised through the issuance of 8,743,720 shares of common stock in October 2025.
• M. Scott Harris, MD, transitioned from Chief Medical Officer to Senior Strategic Advisor on October 1, 2025, with his employment ending by February 28, 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant progress in clinical trials for pemvidutide, including strong MASH data and Fast Track designation for AUD, coupled with a substantially improved liquidity position from recent financing activities. However, this is tempered by ongoing substantial net losses, increased interest expenses, and the emergence of significant legal proceedings (class action and derivative lawsuits) which introduce considerable uncertainty and potential costs.

Positives

• Net loss significantly decreased by 17% for the three months and 16% for the nine months ended September 30, 2025, compared to the prior year periods.
• Cash, cash equivalents, restricted cash, and short-term investments increased substantially to $210.8 million, providing a stronger liquidity position.
• Pemvidutide's IMPACT Phase 2b trial for MASH demonstrated statistically significant MASH resolution (58% and 52% vs 20% placebo) and weight loss (4.8% and 5.8% vs 0.5% placebo).
• An AI-based analysis of the MASH trial showed statistically significant reductions in fibrosis, with 31% of subjects on 1.8 mg achieving a 60% or more reduction.
• Pemvidutide received Fast Track designation from the FDA for Alcohol Use Disorder (AUD), potentially accelerating its development and review.
• Enrollment for the RECLAIM Phase 2 trial in AUD was completed ahead of schedule, indicating strong interest and efficient trial execution.
• The company secured an expanded term loan facility of up to $125.0 million, with $35.0 million already drawn, extending its financial runway.
• Successful at-the-market equity offerings generated over $112.0 million in net proceeds during the nine months ended September 30, 2025, and an additional $33.8 million post-quarter end.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $622.1 million as of September 30, 2025.
• Interest expense increased significantly to $0.8 million for the nine months ended September 30, 2025, compared to $8 thousand in the prior year, due to the new term loan.
• Interest income decreased by $1.4 million for the nine months ended September 30, 2025, despite higher cash balances, indicating potentially lower yields or changes in investment strategy.
• The company has not generated any revenues from product sales to date and there is no assurance of future product sales.
• Fibrosis improvement in the MASH trial without worsening of MASH was not statistically significant (33% and 36% for pemvidutide vs 28% for placebo) in the primary ITT analysis.
• Two significant legal proceedings, a securities class action and a shareholder derivative complaint, have been filed, alleging false and misleading statements related to pemvidutide and the IMPACT trial, which could result in substantial costs and damages.

Risks

• Global tariffs and counter tariffs could negatively impact the global economy, leading to inflationary pressures, supply chain disruptions, and volatility in capital markets, foreign exchange rates, and interest rates.
• A prolonged U.S. government shutdown could significantly delay SEC and FDA review processes, materially affecting business operations.
• The company is subject to ongoing legal proceedings, including a securities class action and a shareholder derivative complaint, which could be costly, divert management resources, and have an adverse impact regardless of the outcome.
• There is no assurance of future revenues from product sales, and the company has incurred significant losses since inception, requiring continuous reliance on financing sources.
• The company will require additional capital beyond currently anticipated amounts to fund its long-term capital needs and planned clinical trials, necessitating further equity or debt financing or partnership arrangements.

Future Outlook

Management believes that current cash on hand, combined with expected cash receipts from equity transactions, is sufficient to fund operations for at least a twelve-month period from the issuance date of the financial statements (November 6, 2025). However, additional capital will be required for long-term needs and planned clinical trials, necessitating further equity or debt financing or partnership arrangements. Topline results for the RECLAIM Phase 2 trial in AUD are expected in 2026.

Management Comments

• Management believes that current cash on hand, together with expected cash receipts from equity transactions, are sufficient to fund operations for at least a twelve-month period from the issuance date of the September 30, 2025 consolidated financial statements.
• To address long-term capital needs, including planned clinical trials, the company must continue to actively pursue additional equity or debt financing, and monetization of existing programs through partnership arrangements or sales to third parties.

Industry Context

Altimmune operates in the highly competitive late clinical-stage biopharmaceutical sector, focusing on novel peptide-based therapeutics for liver and cardiometabolic diseases. The positive Phase 2b MASH data for pemvidutide, particularly the MASH resolution and weight loss, positions it as a potential contender in a rapidly evolving market with significant unmet needs. The pursuit of AUD and ALD indications, coupled with Fast Track designation for AUD, demonstrates a strategy to broaden pemvidutide's market potential and address multiple comorbidities. The company's reliance on equity and debt financing is typical for pre-revenue biotechs, but the substantial capital raises and extended cash runway are critical for advancing its pipeline in this capital-intensive industry.

Comparison to Industry Standards

• NA

Management Changes

Legal Proceedings

• On August 5, 2025, a class action complaint, 'In re Altimmune, Inc. Securities Litigation, Case No. 8:25-cv-02581 (D. Md.)', was filed against the company and two executive officers, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, related to false and misleading statements concerning pemvidutide and the IMPACT Phase 2b trial between August 10, 2023, and June 25, 2025. The company intends to defend vigorously.
• On September 29, 2025, a shareholder derivative complaint, 'Alaraidah v. Altimmune, Inc., et al., No. 8:25-cv-03223 (D. Md.)', was filed on behalf of the company against two executive officers and eight current/former board members. It alleges claims for violations of Section 14(a) of the Securities Exchange Act of 1934, breaches of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution under Sections 10(b) and 21D, based on similar allegations as the class action. The company intends to defend vigorously.

Stakeholder Impact

• Shareholders: Potential for dilution from ongoing at-the-market equity offerings, but also benefit from an extended cash runway and positive clinical trial data. Face uncertainty and potential financial impact from ongoing securities litigation.
• Employees: M. Scott Harris, MD, transitioned from CMO to Senior Strategic Advisor, indicating a change in leadership structure.
• Patients (MASH, AUD, ALD): Progress in clinical trials for pemvidutide offers hope for new therapeutic options for these serious conditions, with Fast Track designation potentially accelerating AUD treatment availability.
• Creditors (Hercules Capital, Inc.): The company secured and expanded a term loan facility, providing additional capital but also increasing debt obligations and interest expense.

Next Steps

• Continue to assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements as additional guidance becomes available.
• Complete the 24-week treatment period and announce topline results for the RECLAIM Phase 2 trial in AUD in 2026.
• Continue to enroll patients in the RESTORE Phase 2 trial for ALD.
• Defend vigorously against the Securities Class Action and Shareholder Derivative Action lawsuits.
• Lead plaintiffs in the Securities Class Action are required to file an amended complaint by November 26, 2025.
• Defendants in the Securities Class Action are required to file an answer or notice of intent to file a motion to dismiss by December 10, 2025.
• Actively pursue additional equity or debt financing, and monetization of existing programs through partnership arrangements or sales to third parties to address long-term capital needs.

Key Dates

Recommendation

Altimmune's Q3 2025 report presents a mixed picture. The positive 24-week MASH Phase 2b data for pemvidutide, including significant MASH resolution and weight loss, is a strong clinical validation and a key driver for future value. The FDA's Fast Track designation for AUD and the ahead-of-schedule enrollment for the RECLAIM trial further de-risk and accelerate the development of pemvidutide. Financially, the company has significantly improved its liquidity through equity offerings and an expanded term loan, extending its cash runway. However, the company remains pre-revenue and continues to incur substantial losses. The most significant new concern is the initiation of two legal proceedings (securities class action and shareholder derivative complaint) alleging misleading statements, which could lead to substantial legal costs, damages, and reputational harm. Given the promising clinical pipeline and improved financial stability, but also the high-risk nature of a pre-revenue biotech and the new legal uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials and the outcomes of the legal proceedings closely.

Keywords

Altimmune, pemvidutide, MASH, AUD, ALD, biopharmaceutical, clinical trial, Phase 2b, glucagon/GLP-1 dual receptor agonist, Fast Track designation, SEC filing, 10-Q, financial results, liquidity, equity offering, term loan, securities litigation